These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18723476)

  • 1. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.
    Tijink BM; Laeremans T; Budde M; Stigter-van Walsum M; Dreier T; de Haard HJ; Leemans CR; van Dongen GA
    Mol Cancer Ther; 2008 Aug; 7(8):2288-97. PubMed ID: 18723476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivalent Rhamnose-Modified EGFR-Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies.
    Li Y; Lin H; Hong H; Li D; Gong L; Zhao J; Wang Z; Wu Z
    Adv Sci (Weinh); 2024 Apr; 11(13):e2307613. PubMed ID: 38286668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
    Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
    Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
    Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
    Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanobodies: natural single-domain antibodies.
    Muyldermans S
    Annu Rev Biochem; 2013; 82():775-97. PubMed ID: 23495938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action.
    Bradley ME; Dombrecht B; Manini J; Willis J; Vlerick D; De Taeye S; Van den Heede K; Roobrouck A; Grot E; Kent TC; Laeremans T; Steffensen S; Van Heeke G; Brown Z; Charlton SJ; Cromie KD
    Mol Pharmacol; 2015 Feb; 87(2):251-62. PubMed ID: 25468882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring antibodies devoid of light chains.
    Hamers-Casterman C; Atarhouch T; Muyldermans S; Robinson G; Hamers C; Songa EB; Bendahman N; Hamers R
    Nature; 1993 Jun; 363(6428):446-8. PubMed ID: 8502296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies.
    Bannas P; Well L; Lenz A; Rissiek B; Haag F; Schmid J; Hochgräfe K; Trepel M; Adam G; Ittrich H; Koch-Nolte F
    Contrast Media Mol Imaging; 2014; 9(2):135-42. PubMed ID: 24523058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanobodies and their potential applications.
    Hassanzadeh-Ghassabeh G; Devoogdt N; De Pauw P; Vincke C; Muyldermans S
    Nanomedicine (Lond); 2013 Jun; 8(6):1013-26. PubMed ID: 23730699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.
    Vosjan MJ; Vercammen J; Kolkman JA; Stigter-van Walsum M; Revets H; van Dongen GA
    Mol Cancer Ther; 2012 Apr; 11(4):1017-25. PubMed ID: 22319202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanobody-based cancer therapy of solid tumors.
    Kijanka M; Dorresteijn B; Oliveira S; van Bergen en Henegouwen PM
    Nanomedicine (Lond); 2015 Jan; 10(1):161-74. PubMed ID: 25597775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.
    Schmitz KR; Bagchi A; Roovers RC; van Bergen en Henegouwen PM; Ferguson KM
    Structure; 2013 Jul; 21(7):1214-24. PubMed ID: 23791944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
    Bannas P; Hambach J; Koch-Nolte F
    Front Immunol; 2017; 8():1603. PubMed ID: 29213270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Therapeutic Potential of Nanobodies.
    Jovčevska I; Muyldermans S
    BioDrugs; 2020 Feb; 34(1):11-26. PubMed ID: 31686399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Easily Established and Multifunctional Synthetic Nanobody Libraries as Research Tools.
    Liu B; Yang D
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
    Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
    Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical development of novel PD-L1 tracers and first-in-human study of [
    Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MICA-specific nanobodies for diagnosis and immunotherapy of MICA
    Verhaar ER; Knoflook A; Pishesha N; Liu X; van Keizerswaard WJC; Wucherpfennig KW; Ploegh HL
    Front Immunol; 2024; 15():1368586. PubMed ID: 38550583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.